Targeting ovarian cancer: The promise of liposome-based therapies.

A major cause of mortality among gynecological cancers, ovarian cancer is frequently unresponsive to standard therapies because to systemic toxicity and medication resistance. The contribution of liposomal drug delivery systems, specifically pegylated liposomal doxorubicin (PLD), to the advancement of ovarian cancer treatment is examined in this review. Liposomes, spherical lipid vesicles consisting of bilayer phospholipids, enable better drug delivery by preserving encapsulated pharmaceuticals and enabling tailored administration to tumor areas. In comparison to traditional doxorubicin, PLD has a better pharmacokinetic profile and less cardiotoxicity, according to the analysis, which examines several trials showing its effectiveness in treating both platinum-sensitive and platinum-resistant ovarian cancer. Furthermore, studies on liposomal versions of other medications, such as paclitaxel and cisplatin, demonstrate encouraging effects in terms of overcoming drug resistance and enhancing therapeutic outcomes. Recent advancements in tailored liposomal delivery systems that include components such tumor-specific peptides and folate receptors show improved tumor selectivity and fewer adverse effects. The study also looks at new combination treatments that use liposomal formulations with immunotherapeutic and new targeted medicines. Although liposomal drug delivery methods have great potential for treating ovarian cancer, further study is required to maximize their effectiveness, reduce side effects, and get beyond resistance mechanisms. These developments in liposomal technology are a major step toward turning ovarian cancer from a deadly illness into a chronic condition that can be managed, possibly increasing patient survival and quality of life.